Cigna has announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the obesity drug class popularized by Novo Nordisk and Eli Lilly becomes a key component of managed care firms' financials. GLP-1 drugs, which include Novo Nordisk's and Eli Lilly's weight loss drugs Wegovy and Zepbound, are a leading cost driver for managed care firms in a market expected to hit more than $100 billion by 2030.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
